Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells

Diana Hanekamp; Lok Lam Ngai; Jeroen J. W. M. Janssen; Arjan van de Loosdrecht; Gert J. Ossenkoppele; Jacqueline Cloos

doi:10.1182/blood.2020007150

Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells

Diana Hanekamp, Lok Lam Ngai, Jeroen J. W. M. Janssen, Arjan van de Loosdrecht, Gert J. Ossenkoppele, Jacqueline Cloos^*

^*Corresponding author for this work

Research output: Contribution to journal › Letter › Academic › peer-review

Original language	English
Pages (from-to)	1694-1697
Number of pages	4
Journal	Blood
Volume	137
Issue number	12
Early online date	10 Nov 2020
DOIs	https://doi.org/10.1182/blood.2020007150 https://doi.org/10.1182/blood.2020007150
Publication status	Published - 25 Mar 2021

Access to Document

Cite this

@article{baacdf73516347019178604cd7f4456f,

title = "Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells",

author = "Diana Hanekamp and Ngai, {Lok Lam} and Janssen, {Jeroen J. W. M.} and {van de Loosdrecht}, Arjan and Ossenkoppele, {Gert J.} and Jacqueline Cloos",

year = "2021",

month = mar,

day = "25",

doi = "10.1182/blood.2020007150",

language = "English",

volume = "137",

pages = "1694--1697",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "12",

}

TY - JOUR

T1 - Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells

AU - Hanekamp, Diana

AU - Ngai, Lok Lam

AU - Janssen, Jeroen J. W. M.

AU - van de Loosdrecht, Arjan

AU - Ossenkoppele, Gert J.

AU - Cloos, Jacqueline

PY - 2021/3/25

Y1 - 2021/3/25

UR - http://www.scopus.com/inward/record.url?scp=85103133852&partnerID=8YFLogxK

U2 - 10.1182/blood.2020007150

DO - 10.1182/blood.2020007150

M3 - Letter

C2 - 33171485

VL - 137

SP - 1694

EP - 1697

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -

Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells

Access to Document

Other files and links

Cite this